Blood Clotting Therapies At
THE HEART OF HUMAN RESILIENCE.
Hemab is pioneering the first targeted preventative treatments and functional cures for underserved bleeding and thrombotic disorders—reimagining the standard of care for patients everywhere.
No Patient With A
The First-Ever Preventative Treatments For
*Currently using monovalent and bispecific antibodies, with intention of expanding to other modalities
Preventing The Full Spectrum Of
Leveraging validated advanced technologies and key insights into the biology of clotting, Hemab’s approach is prime for widespread expansion into a range of underserved bleeding and thrombotic disorders, including Glanzmann Thrombasthenia, Factor VII Deficiency, Hemophilia B with inhibitors, Bernard Soulier Syndrome, Von Willebrand Disease, Hereditary Hemorrhagic Telangiectasia (or Osler-Weber-Rendu disease), Congenital Antithrombin III Deficiency, and others.
We are committed to finding and serving patients that have been left behind despite recent innovative therapies. Our strategic guidance, Hemab 1-2-5TM is targeting development of five clinical assets by 2025 to transform treatment for these rare disorders and enable patients everywhere to live healthy, active lives.
If you have questions about our ongoing clinical trials, please contact firstname.lastname@example.org.
Our expanded access policy can be found here.
Building The Ultimate
Bringing together international experts in clotting biology, patient care, and drug development, the Hemab team is committed to changing the lives of patients with rare clotting disorders all around the world.